Literature DB >> 30233403

Predictive Value of T peak - T end Indices for Adverse Outcomes in Acquired QT Prolongation: A Meta-Analysis.

Gary Tse1,2, Mengqi Gong3, Lei Meng3, Cheuk W Wong4, George Bazoukis5, Matthew T V Chan6, Martin C S Wong7, Konstantinos P Letsas5, Adrian Baranchuk8, Gan-Xin Yan9,10, Tong Liu3, William K K Wu6.   

Abstract

Background: Acquired QT interval prolongation has been linked with malignant ventricular arrhythmias, such as torsade de pointes, in turn predisposing to sudden cardiac death. Increased dispersion of repolarization has been identified as a pro-arrhythmic factor and can be observed as longer Tpeak - Tend interval and higher Tpeak - Tend/QT ratio on the electrocardiogram. However, the values of these repolarization indices for predicting adverse outcomes in this context have not been systematically evaluated. Method: PubMed, Embase and Cochrane Library databases were searched until 14th February 2018, identifying 232 studies.
Results: Five studies on acquired QT prolongation met the inclusion criteria and 308 subjects with drug-induced LQTS patients (mean age: 66 ± 18 years old; 46% male) were included in this meta-analysis. Tpeak - Tend intervals were longer [mean difference [MD]: 76 ms, standard error [SE]: 26 ms, P = 0.003; I2 = 98%] and Tpeak - Tend/QT ratios were higher (MD: 0.14, SE: 0.03, P = 0.000; I2 = 29%) in patients with torsade de pointes compared to those without these events.
Conclusion: Tpeak - Tend interval and Tpeak - Tend/QT ratio were higher in patients with acquired QT prolongation suffering from torsade de pointes compared to those who did not. These repolarization indices may provide additional predictive value for identifying high-risk individuals.

Entities:  

Keywords:  Tpeak—Tend; Tpeak—Tend/QT; dispersion of repolarization; risk stratification; sudden cardiac death; ventricular arrhythmia

Year:  2018        PMID: 30233403      PMCID: PMC6129769          DOI: 10.3389/fphys.2018.01226

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


Introduction

Acquired prolongation of QT interval increases the risk of ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death (SCD). However, patients with prolonged QT intervals are heterogeneous in that only a subset develop these adverse events and risk stratification remains difficult. Of the different electrophysiological mechanisms, exacerbated repolarization gradient across the myocardial wall has been identified as an important factor of arrhythmogenesis in the context of QT prolongation, as it can lead to unidirectional block and reentrant activity (Opthof et al., 2007; Coronel et al., 2009; Choy et al., 2016). On the electrocardiogram, the dispersion of repolarization can be estimated using the Tpeak – Tend Interval, defined as the time difference between the peak and the end of the T-wave. However, this parameter varies with heart rate (Gupta et al., 2008) and normalization with QT interval (Tpeak – Tend/QT ratio) gives a relatively constant range of values between 0.17 and 0.23 (Gupta et al., 2008). Despite their strong physiological basis, the predictive value of both parameters in drug-induced QT prolongation remains controversial. A recent meta-analysis reported that higher Tpeak – Tend interval was predictive of adverse events that include ventricular tachyarrhythmias and sudden cardiac death in congenital long QT syndrome, but it did not investigate its value in cases of acquired QT interval prolongation (Tse et al., 2017a). Nevertheless, several reports have investigated the differences in Tpeak – Tend interval and/or Tpeak – Tend / QT ratio between event-positive and event-negative subjects with acquired QT prolongation with some conflicting results. In this study, we performed a systematic review and meta-analysis to elucidate the relationship between these parameters and adverse events in this patient population.

Methods

Search strategy, inclusion, and exclusion criteria

This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISM) statement (Moher et al., 2015). PubMed, Embase and Cochrane Library were searched for studies that investigated the association between Tpeak – Tend or Tpeak – Tend/QT with arrhythmic or mortality endpoints in long QT syndrome. The following search terms were used for all three databases: [“Tpeak–Tend” OR “Tp-Te” OR “Tpeak-end” OR “Tp-e” OR “T(peak)-T(end)” OR “T wave peak-to-end” OR “T peak-T end” OR “Tpe” “TPEc” OR “T-peak to T-end” OR “Tpeak-to-Tend” AND “long QT”]. The search period was from the beginning of the database through to 14th February 2018 without language restrictions. The following inclusion criteria were used: (i) the study was conducted in humans, (ii) Tpeak – Tend intervals or Tpeak – Tend/QT ratios between event-positive (ventricular tachycardia/fibrillation, or sudden cardiac death) and event-negative groups were compared. The quality assessment of these studies included in our meta-analysis was performed using the Newcastle–Ottawa Quality Assessment Scale (NOS; Marshall et al., 2007). The details of the NOS quality assessment are shown in Supplementary Tables 1, 2. No studies were excluded because of the quality score.

Data extraction and statistical analysis

Data from the different studies were entered in pre-specified spreadsheets in Microsoft Excel (Version 2016). All search entries were retrieved as complete manuscripts and assessed to determine whether they met the inclusion criteria. The extracted data elements consisted of: (i) publication details: last name of first author, publication year; (ii) study design; (iii) endpoint(s); (iv) the quality score; and (v) the characteristics of the population including sample size, gender, age and number of subjects. Two reviewers (GT and MG) reviewed each included study independently. Disagreements were resolved by consulting with a third reviewer (TL). Mean differences with 95% confidence interval (CI) for Tpeak – Tend interval and Tpeak – Tend/QT ratio were extracted from each study and subsequently pooled. Heterogeneity between studies was determined using Cochran's Q-value, the weighted sum of squared differences between individual study effects and the pooled effect across studies, and I2 from the standard chi-square test, which describes the percentage of the variability in effect estimates resulting from heterogeneity. I2 > 50% was considered to reflect significant statistical heterogeneity. A fixed effects model was used if I2 < 50%, otherwise the random-effects model using the inverse variance heterogeneity method was used. To locate the origin of the heterogeneity, sensitivity analysis excluding one study at a time were performed. Funnel plots, Begg and Mazumdar rank correlation test and Egger's test were used to assess for possible publication bias.

Results

A flow diagram of the search strategy is shown in Supplementary Figure 1. Our search retrieved 99 entries from PubMed, 116 entries from Embase and 17 from Cochrane Library. Of these, five studies were relevant for acquired LQTS and were included in our final meta-analysis (Yamaguchi et al., 2003; Topilski et al., 2007; Darbar et al., 2008; Couderc et al., 2010; Subbiah et al., 2010). A total of 308 patients were included (mean age: 66 ± 18 years old; 46% male). Table 1 shows the baseline characteristics of these studies and of the study populations.
Table 1

Characteristics of the five studies included in this meta-analysis.

First author/YearStudy designPopulationDrugsLead for Tpeak–Tend measurementMethod of Tend measurementAdverse eventsSample size (n)Age% MaleEndpointsNo. of patients with any positive eventsReferences
Couderc 2010RetrospectiveDrug-induced LQTSSotololAll 12 leadsTangent methodTdP65067TdP3Couderc et al., 2010
Subbiah 2010ProspectiveAV block with TdPAll 12 leadsTangent methodTdP407040TdP7Subbiah et al., 2010
Darbar 2008RetrospectiveDrug-induced LQTSQuinidine; sotalol, dofetilide, procainamide, disopyramide, amiodarone, trimethoprim-sulfamethoxazole, phenothiazines, Haloperidol, Fluconazole /itraconazole, cisapride, pentamidine, lithium, terfernadine, clarithromycinAll 12 leadsBaseline methodTdP1235920TdP83Darbar et al., 2008
Topilski 2007RetrospectiveAV block with TdPAll 12 leadsBaseline methodTdP1437619TdP30Topilski et al., 2007
Yamaguchi 2003ProspectiveDrug-induced LQTS (10 different drugs)Bepridil, pirmenol, ranitidine, disopyramide, probucol, aprindine, diazepam, pilsicainide, clonazepamV5Tangent methodTdP276629TdP12Yamaguchi et al., 2003

LQTS, long QT syndrome; TdP, torsade de pointes.

Characteristics of the five studies included in this meta-analysis. LQTS, long QT syndrome; TdP, torsade de pointes. The Tpeak – Tend intervals for event-negative (Figure 1A, top panel) and event-positive groups (Figure 1A, middle panel) were 96 ± 14 and 165 ± 15, respectively, with a significant mean difference of 76 ± 26 ms (P = 0.003, I2 = 98%) (Figure 1A, bottom panel). Moreover, the Tpeak – Tend/QT ratio for event-negative (Figure 1B, top panel) and event-positive (Figure 1B, middle panel) groups were 0.19 ± 0.01 and 0.29 ± 0.04, respectively, with a significant mean difference of 0.14 ± 0.03 (P < 0.0001; I2 = 29%) (Figure 1B, bottom panel). The results from bias analyses are shown in the Supplementary Material.
Figure 1

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation.

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation. Subgroup analysis based on the cause of acquired LQTS was performed. A meta-analysis of three studies examining drug-induced LQTS found that Tpeak – Tend intervals for event-negative (Figure 2A, top panel) and event-positive groups (Figure 2A, middle panel) took values of 108 ± 19 and 149 ± 16, respectively. However, the mean difference of 44 ± 28 ms did not reach statistical significance (P = 0.12; I2 = 94%; Figure 2A, bottom panel). Tpeak – Tend / QT ratios took values of 0.20 ± 0.02 and 0.27 ± 0.05 for event-negative (Figure 2B, top panel) and event-positive (Figure 2B, middle panel) groups, respectively, with a significant mean difference between both groups (0.13 ± 0.03, P < 0.0001; I2 = 22%; Figure 2B, bottom panel).
Figure 2

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in drug-induced QT prolongation.

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in drug-induced QT prolongation. For AV block-induced LQTS, two studies were meta-analyzed. Tpeak – Tend intervals for event-negative (Figure 3A, top panel) and event-positive groups (Figure 3A, middle panel) were 79 ± 14 and 194 ± 49, respectively, leading to a significant mean difference of 124 ± 54 ms (P = 0.02; I2 = 99%; Figure 3A, bottom panel). By contrast, Tpeak – Tend / QT ratios took values of 0.18 ± 0.06 and 0.5 ± 0.06 for event-negative (Figure 3B, top panel) and event-positive (Figure 3B, middle panel) groups, respectively, but the mean difference between both groups was not significant (0.13 ± 0.11, P = 0.27; I2 = 66%; Figure 3B, bottom panel).
Figure 3

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in AV block-induced QT prolongation.

Forest plot demonstrating the (A) mean Tpeak – Tend intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean Tpeak – Tend/QT ratios in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in AV block-induced QT prolongation. Finally, QTc intervals for event-negative (Figure 4A, top panel) and event-positive groups (Figure 4A, middle panel) took values of 412 ± 104 and 594 ± 17, respectively, with a significant difference between both groups (180 ± 80 ms; P = 0.02; I2 = 99%; Figure 4A, bottom panel). Heart rates for event-negative (Figure 4B, top panel) and event-positive groups (Figure 4B, middle panel) took values of 56 ± 9 and 58 ± 9, respectively, with no significant mean difference between both groups (2 ± 1 ms; P = 0.26; I2 = 0%; Figure 4B, bottom panel).
Figure 4

Forest plot demonstrating the (A) mean QTc intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean heart rate in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation.

Forest plot demonstrating the (A) mean QTc intervals in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation, and (B) mean heart rate in the event-negative group (top panel), event-positive group (middle panel) and difference between both groups (bottom panel) in acquired QT prolongation.

Discussion

The major findings of this systematic review and meta-analysis of 308 acquired LQTS subjects are that Tpeak – Tend intervals were longer by 76 ± 26 ms and Tpeak – Tend/QT ratios were higher by 0.14 ± 0.03 in those who exhibited adverse events compared with those who did not. QTc were also longer by 180 ± 80 ms but no difference in heart rate was observed. Tpeak – Tend represent the global dispersion of repolarization (Xia et al., 2005) and its prolongation has been associated with arrhythmogenesis in conditions such as Brugada syndrome, heart failure, myocardial infarction (Tse et al., 2017a,b). Recently, our group conducted a meta-analysis of the predictive values of Tpeak – Tend and Tpeak – Tend / QT ratios in congenital LQTS (Tse et al., 2018). This study extends these findings by providing evidence that Tpeak – Tend intervals and Tpeak – Tend/QT ratios are valuable for risk stratification in acquired QT prolongation. Importantly, it shows that such have different risks of adverse outcomes, and that Tpeak – Tend intervals, Tpeak – Tend/QT ratios and QTc intervals can be used to identify those who are most at risk. Besides the studies included in this meta-analysis, a large retrospective study compared the outcomes between 293 acquired LQTS subjects and 542 subjects without LQTS (Yu et al., 2017). They found significantly longer QTC intervals associated with higher incidences of life-threatening ventricular arrhythmias as well as one-year mortality in the acquired LQTS group. However, there was no further risk stratification within the acquired LQTS group into survivors and non-survivors using the different ECG indices reported here. Further work is needed to examine whether Tpeak – Tend, Tpeak – Tend/QT ratio and QTc interval are significant predictors of arrhythmic and mortality events, and to compare their relative sensitivity and specificity. In our meta-analysis, patients with acquired LQTS due to both drugs and complete AV block were included. Clearly, the mechanisms underlying QT prolongation in these respective groups are different. Thus, drugs that inhibit the outward potassium ion channels can lead to delayed ventricular repolarization, leading to action potential prolongation and lengthening of the QT interval. Whilst drug or metabolic causes of QT lengthening are more common, the original descriptions of torsade de pointes associated with QT prolongation by Dessertenne involved complete AV block (Dessertenne, 1966). The underlying causes may be dysfunction of more than one potassium ion channel (Topilski et al., 2007). Our subgroup analysis found that Tpeak – Tend/QT ratios, but not Tpeak – Tend intervals, were higher in event-positive subjects with drug-induced LQTS, whereas the converse was true for patients with AV block. However, this may be due to the small sample size and number of studies included. In addition to QT, QTc, Tpeak – Tend intervals and Tpeak – Tend/QT ratio, additional ECG parameters have been proposed for risk stratification (Tse and Yan, 2016). Static markers such as JTPeak prolongation have been shown to predict adverse events in drug-induced LQTS beyond QTc (Johannesen et al., 2016). A new biomarker termed index of Cardiac Electrophysiological Balance (iCEB), an ECG surrogate of excitation wavelength (Tse, 2016), has been shown to predict ventricular arrhythmias associated with dofetilide-induced QT prolongation (Lu et al., 2013) and beyond (Robyns et al., 2016). Dynamic markers include T-wave alternans (TWA) (Zareba et al., 1994), microvolt TWAs (Takasugi et al., 2016), beat-to-beat variability in repolarization (Couderc et al., 2007, 2009; Hinterseer et al., 2008, 2009, 2010; Pueyo et al., 2011) and restitution indices (Nicolson et al., 2012, 2014), all of which have demonstrated predictability for arrhythmic outcomes. These dynamic markers may be provide additional value beyond QTc intervals, as illustrated by the findings that short-term variability in QT intervals was higher in drug-induced LQTS compared to controls, whereas QTc interval was not significantly different between these two groups (Hinterseer et al., 2008). It is unsurprising that variability in repolarization, rather than just the baseline repolarization properties, can further provide risk stratification because arrhythmias do not occur in every individual with prolonged QTc or Tpeak – Tend intervals. Instead, these dynamic factors can either initiate the arrhythmia or provide an additional abnormal substrate that further elevates the risk of re-entry (Thomsen et al., 2004; Tse et al., 2016b).

Limitations

The following limitations should be recognized. Firstly, the heterogeneity was substantial in our meta-analysis of the mean difference for Tpeak – Tend intervals, with I2 taking a value of 98%. This compared to a low level of heterogeneity for Tpeak – Tend/QT ratios with I2 of 29%. The reason may be due to different methods for determining Tend, which significantly affects the values of Tpeak – Tend intervals obtained. Two studies used the tangent method by taking the intersection of a tangent to the steepest downslope of the dominant repolarization wave with the isoelectric line, whereas the remaining study used the point at which the T-wave intersected with the isoelectric line. By contrast, Tend cancels out in Tpeak – Tend/QT ratios as it appears in both the numerator and denominator, thereby reducing the influence of Tend on the calculated ratio. Secondly, considerable inter-observer variability is likely present because Tpeak – Tend were measured by investigators from different research groups. Thirdly, recall bias may have been present in the retrospective studies, which could have also contributed to some of the heterogeneity observed. Fourthly, the baseline characteristics of the included studies were different, in that one study examined outcomes in the pediatric population whereas two studies were on adult populations. Fifthly, electrolyte abnormalities, most frequently hypokalemia, can also lead to delayed repolarization and consequently QT lengthening (Lee et al., 2003; Hanton et al., 2007; Tse et al., 2016a,c). Thus, potassium levels can be a confounder in further altering the QT interval. Further studies should therefore specify the plasma K+ concentrations at the time of ECG measurements where possible. Finally, although traditionally prolonged QT intervals have been categorized into congenital and acquired causes, recent epidemiological studies reveal a complex relationship between genetics and the environment. Specifically, missense variants in ion channel genes such as the SCN5A that encode for the cardiac voltage-gated sodium channel, can potentiate the effects of hypokalaemia-induced QT prolongation (Akylbekova et al., 2014).

Conclusions

In the context of acquired QT prolongation, Tpeak – Tend intervals were longer and Tpeak – Tend / QT ratios were higher in patients showing adverse events than in those who did not suffer from these events. These repolarization indices may therefore be useful for risk stratification in this patient population.

Author contributions

GT: conception of study, data extraction and analysis, data interpretation, manuscript draft, critical revision of manuscript; MG: data extraction and analysis, data interpretation, manuscript draft, critical revision of manuscript; All authors: data interpretation, critical revision of manuscript; WW and TL: study supervision.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  39 in total

1.  Dispersion of repolarization and arrhythmogenesis.

Authors:  Ruben Coronel; Francien J G Wilms-Schopman; Tobias Opthof; Michiel J Janse
Journal:  Heart Rhythm       Date:  2009-01-18       Impact factor: 6.343

2.  A multiscale investigation of repolarization variability and its role in cardiac arrhythmogenesis.

Authors:  Esther Pueyo; Alberto Corrias; László Virág; Norbert Jost; Tamás Szél; András Varró; Norbert Szentandrássy; Péter P Nánási; Kevin Burrage; Blanca Rodríguez
Journal:  Biophys J       Date:  2011-12-20       Impact factor: 4.033

3.  Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure.

Authors:  Martin Hinterseer; Britt-Maria Beckmann; Morten B Thomsen; Arne Pfeufer; Michael Ulbrich; Moritz F Sinner; Siegfried Perz; H-Erich Wichmann; Csaba Lengyel; Rainer Schimpf; Sebastian K G Maier; András Varró; Marc A Vos; Gerhard Steinbeck; Stefan Kääb
Journal:  Am J Cardiol       Date:  2010-07-15       Impact factor: 2.778

4.  [Ventricular tachycardia with 2 variable opposing foci].

Authors:  F Dessertenne
Journal:  Arch Mal Coeur Vaiss       Date:  1966-02

Review 5.  The Tpeak - Tend interval as an electrocardiographic risk marker of arrhythmic and mortality outcomes: A systematic review and meta-analysis.

Authors:  Gary Tse; Mengqi Gong; Wing Tak Wong; Stamatis Georgopoulos; Konstantinos P Letsas; Vassilios S Vassiliou; Yat Sun Chan; Bryan P Yan; Sunny Hei Wong; William K K Wu; Ana Ciobanu; Guangping Li; Jayaprakash Shenthar; Ardan M Saguner; Sadeq Ali-Hasan-Al-Saegh; Aishwarya Bhardwaj; Abhishek C Sawant; Paula Whittaker; Yunlong Xia; Gan-Xin Yan; Tong Liu
Journal:  Heart Rhythm       Date:  2017-05-26       Impact factor: 6.343

6.  The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.

Authors:  Ian Topilski; Ori Rogowski; Rafael Rosso; Dan Justo; Yitschak Copperman; Michael Glikson; Bernard Belhassen; Marek Hochenberg; Sami Viskin
Journal:  J Am Coll Cardiol       Date:  2007-01-04       Impact factor: 24.094

7.  Meta-analysis of Tpeak-Tend and Tpeak-Tend/QT ratio for risk stratification in congenital long QT syndrome.

Authors:  Gary Tse; Mengqi Gong; Lei Meng; Cheuk Wai Wong; Stamatis Georgopoulos; George Bazoukis; Martin C S Wong; Konstantinos P Letsas; Vassilios S Vassiliou; Yunlong Xia; Adrian M Baranchuk; Gan-Xin Yan; Tong Liu
Journal:  J Electrocardiol       Date:  2018-03-06       Impact factor: 1.438

8.  Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.

Authors:  Dawood Darbar; John Kimbrough; Asif Jawaid; Robert McCray; Marylyn D Ritchie; Dan M Roden
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

9.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01

Review 10.  Cardiac disease and arrhythmogenesis: Mechanistic insights from mouse models.

Authors:  Lois Choy; Jie Ming Yeo; Vivian Tse; Shing Po Chan; Gary Tse
Journal:  Int J Cardiol Heart Vasc       Date:  2016-09
View more
  12 in total

1.  Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19.

Authors:  Abdulmecit Afsin; Kenan Ecemis; Ramazan Asoglu
Journal:  J Clin Med Res       Date:  2020-08-15

2.  The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.

Authors:  Nijad Bakhshaliyev; Ramazan Özdemir
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-05-06       Impact factor: 1.468

3.  Common Genetic Variants Modulate the Electrocardiographic Tpeak-to-Tend Interval.

Authors:  Julia Ramírez; Stefan van Duijvenboden; William J Young; Michele Orini; Pier D Lambiase; Patricia B Munroe; Andrew Tinker
Journal:  Am J Hum Genet       Date:  2020-05-07       Impact factor: 11.025

4.  The ECG Characteristics of Patients With Isolated Hypomagnesemia.

Authors:  Yiheng Yang; Cheng Chen; Penghong Duan; Suman Thapaliya; Lianjun Gao; Yingxue Dong; Xiaomeng Yin; Xiaolei Yang; Rongfeng Zhang; Ruopeng Tan; Simei Hui; Yue Wang; Richard Sutton; Yunlong Xia
Journal:  Front Physiol       Date:  2021-01-27       Impact factor: 4.566

5.  Ventricular repolarization heterogeneity in patients with COVID-19: Original data, systematic review, and meta-analysis.

Authors:  Elham Mahmoudi; Reza Mollazadeh; Pejman Mansouri; Mohammad Keykhaei; Shayan Mirshafiee; Behnam Hedayat; Mojtaba Salarifar; Matthew F Yuyun; Hirad Yarmohammadi
Journal:  Clin Cardiol       Date:  2022-01-10       Impact factor: 3.287

6.  Transient Acquired QT Interval Prolongation After Administration of Intravenous Ondansetron.

Authors:  Ruochen Mao; Evan J Wiens; Basem Elbarouni
Journal:  CJC Open       Date:  2021-08-24

7.  QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia.

Authors:  Rizki A Gumilang; Vita Y Anggraeni; Ika Trisnawati; Eko Budiono; Anggoro B Hartopo
Journal:  J Arrhythm       Date:  2021-08-28

8.  Exercise-induced electrocardiographic changes after treadmill exercise testing in healthy children: A comprehensive study.

Authors:  Elaheh Malakan Rad; Mohsen Karimi; Sara Momtazmanesh; Reza Shabanian; Mohammad Saatchi; Parvin Akbari Asbagh; Ali Akbar Zeinaloo
Journal:  Ann Pediatr Cardiol       Date:  2022-03-25

Review 9.  Analysing electrocardiographic traits and predicting cardiac risk in UK biobank.

Authors:  Julia Ramírez; Stefan van Duijvenboden; William J Young; Michele Orini; Aled R Jones; Pier D Lambiase; Patricia B Munroe; Andrew Tinker
Journal:  JRSM Cardiovasc Dis       Date:  2021-06-12

10.  Commentary: Assessment of Hypertension Using Clinical Electrocardiogram Features: A First-Ever Review.

Authors:  Tatsuya Sato
Journal:  Front Med (Lausanne)       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.